Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker.
about
Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discoveryMale breast cancer: risk factors, biology, diagnosis, treatment, and survivorshipA novel color change mechanism for breast cancer biomarker detection: naphthoquinones as specific ligands of human arylamine N-acetyltransferase 1From arylamine N-acetyltransferase to folate-dependent acetyl CoA hydrolase: impact of folic acid on the activity of (HUMAN)NAT1 and its homologue (MOUSE)NAT2The footprint of the ageing stroma in older patients with breast cancer.Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypesThe landscape of candidate driver genes differs between male and female breast cancer.Expression of connective tissue growth factor in male breast cancer: clinicopathologic correlations and prognostic valueImmunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancerGene expression profiling leads to discovery of correlation of matrix metalloproteinase 11 and heparanase 2 in breast cancer progression.An international comparison of male and female breast cancer incidence ratesCharacterization of Korean Male Breast Cancer Using an Online Nationwide Breast-Cancer Database: Matched-Pair Analysis of Patients With Female Breast Cancer.Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse.Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancerHMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.Characterisation of male breast cancer: a descriptive biomarker study from a large patient series.Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations.The cancer genetics and pathology of male breast cancer.Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma.Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer.Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.Genome methylation patterns in male breast cancer - Identification of an epitype with hypermethylation of polycomb target genes.Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression.Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer.Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact.Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.Immunophenotyping of male breast cancer.Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.High proliferation is associated with inferior outcome in male breast cancer patients.Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.The Unknown microRNA Expression of Male Breast Cancer. Similarities and Differences with Female Ductal Carcinoma. Their Role as Tumor Biomarker.Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series.Male Breast Cancer.The 21-Gene Recurrence Score in Male Breast Cancer.Perspective: Not just for women.Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance.Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer
P2860
Q26995125-EEF0910C-BA59-4C96-B735-E6174490AAC1Q27025244-42A62C88-AF1A-468C-9F64-7BC00B6BE5B6Q28535117-0DAC7C97-3104-4C48-A31D-5B463C5D5440Q28538748-95A2373D-6B56-4B72-9CF6-AE1EA305AB7DQ33864284-7503EED4-59A7-4A83-9C00-BC310BBED790Q34199368-BD637C19-5DB4-45DF-B54E-A8E567848949Q35032523-1BCB0D28-EE5C-4A2B-A6A2-B48447FCB31BQ35148021-BCCD682A-A7A3-4C00-A467-F4A73E12363EQ35189523-49C3BDE3-9B16-489D-B42F-E16937C0C31EQ35769433-5598F3A8-44DA-4438-978C-096CEF9A4474Q36557024-596F13EA-CB9F-44AF-9528-5339D91B61A7Q36837977-F2E1A3BC-F938-494E-9864-427F0512CDC8Q36939031-DA83AAD9-F7AB-480A-80D8-CE49B240F9DFQ37151073-DE50C6F8-CF87-4365-9CC9-AE17C20A2302Q37319005-68F0D7EE-38A9-4A67-B296-B25B3375AAD6Q37536519-4258557C-C380-4781-A9B4-F76F02D87B41Q37690197-4134F136-49A4-49A8-863C-EC9F4273B0C6Q37723938-CF77AC13-16EC-4560-A4FC-DE02A46A6D71Q38239410-0F41C2E3-56CE-4955-9FBD-D0DCA4BD597DQ38696800-5E5C7FDB-BF2B-4EB7-BF8F-E7C843EAC065Q39253863-C89C7000-F956-4411-A32B-7D011DBE4B73Q40420136-B5007F47-2881-4B71-B011-112679462328Q40573572-43E26AE6-1546-47E3-A27F-26CDEFF340E2Q41136382-1B577BC6-42BE-49C3-A5A8-99D319BBD7BAQ41388351-08F9268E-F45A-4F3A-8AFE-29CEA8422FC8Q42453016-A879E78D-BA2F-415A-8B9A-BCCF3A0A02D8Q42511904-1AA19A06-55FD-46C1-AE63-1CCBFFB69779Q42516409-A505FBD1-7C94-41FB-A48A-1E7837CC1870Q43891146-3DBFB1BC-EE85-472F-9238-6C507E2743F2Q44595171-9996894E-B582-4B5B-B34B-5F9CC5697861Q46532481-4DF9EE83-DF81-422B-95F4-8933F8332AD0Q47593035-13E0F070-F874-4204-9E45-EFF7B3EC0D4BQ48112811-2149B39C-D8D1-4AC9-A383-8DAFC0986730Q50292125-B6BB5FFD-5514-4474-AAFC-B2EC310E62E6Q51112229-B5E29CF1-95ED-4BEC-B677-6364F5FFF6D2Q51148400-DE2D70C4-6EE9-4CB5-BBB1-27E4620D3DD6Q52665411-793FE8D0-A5CD-493E-B195-84CC8F99000CQ52843586-7866C2F9-F5E0-4F14-B361-4AA3BB47B8AAQ55518016-2106A749-F1C6-4B84-BC21-A177B10BB4A2Q58709910-C74EE041-5A89-4B87-95AA-755399349DBC
P2860
Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Gene expression profiling of p ...... a novel prognostic biomarker.
@ast
Gene expression profiling of p ...... a novel prognostic biomarker.
@en
type
label
Gene expression profiling of p ...... a novel prognostic biomarker.
@ast
Gene expression profiling of p ...... a novel prognostic biomarker.
@en
prefLabel
Gene expression profiling of p ...... a novel prognostic biomarker.
@ast
Gene expression profiling of p ...... a novel prognostic biomarker.
@en
P2093
P2860
P50
P356
P1476
Gene expression profiling of p ...... a novel prognostic biomarker.
@en
P2093
Cecilia Nilsson
Ida Johansson
Marie-Louise Fjällskog
Markus Ringnér
Martin Lauss
Pontus Berglund
Sten Thorstensson
P2860
P2888
P356
10.1186/BCR3116
P577
2012-02-14T00:00:00Z
P5875
P6179
1020943037